Concorde Asset Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Concorde Asset Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,526	Closed	-$284K	–	124
2017 Q4	$284K	Sell	6,526 -1,340	-17%	-$57K	0.36%	87
2017 Q3	$340K	Sell	7,866 -974	-11%	-$41.3K	0.29%	97
2017 Q2	$380K	Sell	8,840 -1,038	-11%	-$43.8K	0.51%	71
2017 Q1	$410K	Sell	9,878 -2,735	-22%	-$111K	0.68%	52
2016 Q4	$429K	Sell	12,613 -2,013	-14%	-$81.9K	0.77%	50
2016 Q3	$646K	Sell	14,626 -1,721	-11%	-$78.1K	0.81%	37
2016 Q2	$629K	Sell	16,347 -4,360	-21%	-$185K	0.63%	37
2016 Q1	$843K	Sell	20,707 -4,405	-18%	-$187K	0.97%	28
2015 Q4	$1.29M	Sell	25,112 -426	-2%	-$21.7K	1.43%	20
2015 Q3	$1.2M	Buy	25,538 +1,674	+7%	+$101K	2.03%	13
2015 Q2	$1.49M	Buy	+23,864	New	+$1.49M	1.89%	17

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Arnhold LLC New York $1.43B AUM 59.3% 1-Year Est. Return

Concorde Asset Management's XPH Position: Q1 2018 in Review

Concorde Asset Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2018, closing a stake of 6,526 shares — an estimated $284K sold.

Concorde Asset Management first reported a position in XPH in Q2 2015 and held it in 11 quarters. The position peaked at $1.49M in Q2 2015. 75 funds tracked by Wall St. Rank hold XPH as of Q1 2018.

Concorde Asset Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2018 after selling out during the quarter.
Concorde Asset Management sold 6,526 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2018, an estimated $284K.
Concorde Asset Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2015 and held it in 11 quarters.
Concorde Asset Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.49M in Q2 2015.
75 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2018.

Based on Concorde Asset Management's 13F filing for Q1 2018, filed 24 Apr 2018.